SCHEMBL4140717

SCHEMBL4140717

O=C(O)CC(=C1SC(Nc2ccc(CC(=O)O)cc2)=NC1=O)c1c[nH]c2ccccc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 1/20 0.42
CFTR P13569 2/20 0.40
ADAM17 P78536 1/20 0.40
GABRP O00591 4/20 0.39
GABRD O14764 4/20 0.39
GABRA1 P14867 4/20 0.39
GABRB1 P18505 4/20 0.39
GABRG2 P18507 4/20 0.39
GABRB3 P28472 4/20 0.39
GABRA5 P31644 4/20 0.39
GABRA3 P34903 4/20 0.39
GABRA2 P47869 4/20 0.39
GABRB2 P47870 4/20 0.39
GABRA4 P48169 4/20 0.39
GABRE P78334 4/20 0.39
GABRA6 Q16445 4/20 0.39
GABRG1 Q8N1C3 4/20 0.39
GABRG3 Q99928 4/20 0.39
GABRQ Q9UN88 4/20 0.39
PDE4B Q07343 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4132050 0.93 PTGDR2 (0.40) PTGDR2CFTRADAM17GABRPGABRD
SCHEMBL4294902 0.90 ADAM17 (0.43) PTGDR2CFTRADAM17GABRPGABRD
SCHEMBL4122099 0.89 PTGDR2 (0.39) PTGDR2CFTRADAM17GABRPGABRD
SCHEMBL4137011 0.83 SIRT2 (0.40) PTGDR2CFTRADAM17GABRPGABRD
SCHEMBL4122132 0.82 IGF1R (0.41) PTGDR2CFTRNPC1RAB9AMEN1
SCHEMBL4666978 0.78 ALDH1A1 (0.41) CFTRADAM17GABRPGABRDGABRA1
SCHEMBL4136333 0.78 PDE4B (0.39) PTGDR2CFTRPDE4BNPC1RAB9A
SCHEMBL4136331 0.78 PDE4B (0.39) PTGDR2CFTRPDE4BNPC1RAB9A
SCHEMBL4128196 0.73 POLB (0.39) PTGDR2NPC1RAB9AMEN1KMT2A
SCHEMBL4129357 0.72 NR1H4 (0.38) PDE4BRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP claimed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP disclosed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ PTGDR2 2360/4885CFTR 243/4885ADAM17 2119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.